| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:34 UTC |
|---|
| HMDB ID | HMDB0014323 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Valsartan |
|---|
| Description | Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease. |
|---|
| Structure | CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine | ChEBI | | Diovan | ChEBI | | N-(p-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine | ChEBI | | N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine | ChEBI | | Vals | HMDB | | N-Valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine | HMDB | | Tareg | HMDB | | Kalpress | HMDB | | Miten | HMDB | | Provas | HMDB | | Nisis | HMDB |
|
|---|
| Chemical Formula | C24H29N5O3 |
|---|
| Average Molecular Weight | 435.5188 |
|---|
| Monoisotopic Molecular Weight | 435.227039819 |
|---|
| IUPAC Name | (2S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid |
|---|
| Traditional Name | valsartan |
|---|
| CAS Registry Number | 137862-53-4 |
|---|
| SMILES | CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1 |
|---|
| InChI Key | ACWBQPMHZXGDFX-QFIPXVFZSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as valine and derivatives. Valine and derivatives are compounds containing valine or a derivative thereof resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of glycine by a heteroatom. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Amino acids, peptides, and analogues |
|---|
| Direct Parent | Valine and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - N-acyl-alpha-amino acid
- Valine or derivatives
- N-acyl-alpha amino acid or derivatives
- N-acyl-l-alpha-amino acid
- Biphenyl
- Phenyltetrazole
- Monocyclic benzene moiety
- N-acyl-amine
- Benzenoid
- Azole
- Heteroaromatic compound
- Tertiary carboxylic acid amide
- Tetrazole
- Carboxamide group
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Azacycle
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Hydrocarbon derivative
- Organic oxide
- Organopnictogen compound
- Carbonyl group
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aromatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 116 - 117 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.023 g/L | Not Available | | LogP | 5.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter)). Predicted by Afia on May 17, 2022. | 7.3 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 15.7103 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 1.6 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 50.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2757.0 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 293.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 217.2 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 181.8 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 214.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 615.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 634.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 78.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1365.2 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 595.2 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1528.7 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 414.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 408.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 200.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 85.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Valsartan,1TMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C)C(C)C | 3416.4 | Semi standard non polar | 33892256 | | Valsartan,1TMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)[C@H](C(=O)O)C(C)C | 3626.8 | Semi standard non polar | 33892256 | | Valsartan,2TMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C)C(C)C | 3585.9 | Semi standard non polar | 33892256 | | Valsartan,2TMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C)C(C)C | 3530.6 | Standard non polar | 33892256 | | Valsartan,2TMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C)C(C)C | 4470.1 | Standard polar | 33892256 | | Valsartan,1TBDMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=N[NH]N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C(C)C | 3613.3 | Semi standard non polar | 33892256 | | Valsartan,1TBDMS,isomer #2 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)[C@H](C(=O)O)C(C)C | 3743.1 | Semi standard non polar | 33892256 | | Valsartan,2TBDMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C(C)C | 3890.1 | Semi standard non polar | 33892256 | | Valsartan,2TBDMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C(C)C | 3989.9 | Standard non polar | 33892256 | | Valsartan,2TBDMS,isomer #1 | CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NN([Si](C)(C)C(C)(C)C)N=N2)C=C1)[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C(C)C | 4493.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Valsartan GC-MS (Non-derivatized) - 70eV, Positive | splash10-000i-3094000000-1a2b93c2e5e760118ffd | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valsartan GC-MS (1 TMS) - 70eV, Positive | splash10-052u-9236700000-2f92b4642db0f6e1db76 | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Valsartan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-qTof , Positive-QTOF | splash10-0a4i-0122900000-e2d5ae1b4433254a8ebe | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-qTof , Positive-QTOF | splash10-0a4u-1492000000-bc19c44b1bd382b3180f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-QTOF , negative-QTOF | splash10-001i-0000900000-45397dbc5403f1111d85 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-QTOF , negative-QTOF | splash10-003r-0303900000-1056988fef13dc9becc8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-QTOF , negative-QTOF | splash10-004i-0900000000-65d8dfbf9280fcea77fb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-QTOF , negative-QTOF | splash10-004i-0900000000-77a9588a3e936c9d2e28 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-0udi-0009000000-160f82ad0952fc9b3350 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0000900000-d7bf9d8976f47e44ab4a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-0fb9-0915000000-1f5a4e134cd8450810e7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0900000000-19095db3835430e9fe16 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0900000000-00e9b9924b37c4db7a8d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0900000000-fb8741bb91ee87d8245e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-001i-0000900000-be5ab1c8cde8851235e3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-0fb9-0915000000-08501c181e1066f2aa0a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0900000000-6cabcfa5948837eddb2e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0900000000-d0aedd0bab06b374571a | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-004i-0901000000-a4572421f0a393f299a1 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-ITFT , negative-QTOF | splash10-0udi-0009000000-0f743f9e78dce83f2414 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valsartan LC-ESI-QFT , negative-QTOF | splash10-003r-0912600000-feeef5a05d8ef569460d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 10V, Positive-QTOF | splash10-000i-1055900000-71633e9ccff4a2e3fddf | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 20V, Positive-QTOF | splash10-000i-3089200000-21a5c13b314fa930073e | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 40V, Positive-QTOF | splash10-052r-4293000000-5b414a2cac94b4c0bad5 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 10V, Negative-QTOF | splash10-000x-0009600000-4157b99813121a9c94ea | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 20V, Negative-QTOF | splash10-0f8c-1119200000-f3f0fc40c02029f25882 | 2017-07-26 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valsartan 40V, Negative-QTOF | splash10-00xu-5906000000-9ea0192d8fb20dac6ee7 | 2017-07-26 | Wishart Lab | View Spectrum |
|
|---|